Table 1.
Cohort baseline clinical characteristics.
| Patient ID | Baseline demographics | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sex | ECOG | Age of diagnosis of primary | Anatomic location of primary | Site of metastatic disease | BRAF mutation | Duration of BRAF/MEKi | LDH baseline | M1 status | Brain met | Burden of disease | Age at commencement of Pembrolizumab | |
| 173 | F | N/A | 70 | Vulvar mucosa | LN | No | No | 128 | a | No | Low | 75 |
| 205 | M | 0 | 75 | Leg | Lung | No | No | 121 | b | No | Low | 80 |
| 206 | F | 1 | 55 | Leg | SC, LN | No | No | 196 | a | No | N/A | 61 |
| 209 | M | 0 | 49 | Back | Lung, LN | No | No | 160 | b | No | Low | 55 |
| 213 | F | 0 | 68 | Face | Breast, lung, bone | No | No | 167 | c | No | N/A | 72 |
| 216 | M | 0 | 72 | Toe | Lung, dermal | No | No | 153 | b | Yes | Low | 75 |
| 218 | M | N/A | No primary | N/A | Adrenal, bone, retroperitoneal LN | Yes | 12 m/prog | 303 | c | Yes | N/A | 63 |
| 219 | M | 0 | 43 | Right neck | LN, liver | Yes | 9 m/prog | N/A | c | No | N/A | 48 |
| 220 | F | 1 | No primary | N/A | Lung, pleura, LN, bone, brain, liver | Yes | 11 m/prog | 313 | c | Yes | High | 67 |
| 254 | M | N/A | 64 | Back | Liver, skin, small bowel | No | No | 235 | a | No | Low | 73 |
| 257 | F | 1 | No primary | N/A | Brain, lung | No | No | 224 | c | Yes | High | 63 |
| 259 | M | N/A | N/A | N/A | Lung, bowel | Yes | 15 m/prog | 164 | c | N/A | N/A | 52 |
| 266 | M | 0 | 40 | Sternum | Small bowel, LN | No | No | 179 | c | No | Low | 46 |
| 296 | M | 0 | 61 | Right calf/leg | LN, SC | No | No | N/A | a | No | Low | 69 |
| 318 | M | 1 | 74 | Left arm | Brain, adrenal LN, SC | No | No | N/A | c | Yes | High | 79 |
| 333 | M | 0 | 72 | Right back | Brain, lung, pleura, rib | No | No | 164 | c | Yes | Low | 75 |
N/A, not available; prog, progression; LN, Lymph node; sc, sub-cutaneous.